Synopsis
Synopsis
0
CEP/COS
0
JDMF
0
EU WC
0
VMF
0
Listed Suppliers
0
EDQM
0
USP
0
JP
0
Others
0
Listed Dossiers
DRUG PRODUCT COMPOSITIONS
Regulatory FDF Prices
NA
0
API
0
FDF
0
Data Compilation #PharmaFlow
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers


1. (7s)-2-(4-phenoxyphenyl)-7-(1-(prop-2-enoyl)piperidin-4-yl)-4,5,6,7-tetrahydropyrazolo(1,5-a)pyrimidine-3-carboxamide
2. 7-(1-acryloyl-4-piperidinyl)-2-(4-phenoxyphenyl)-4,5,6,7-tetrahydropyrazolo(1,5-a)pyrimidine-3-carboxamide
3. Bgb-3111
4. Brukinsa
1. 1691249-45-2
2. Brukinsa
3. Bgb-3111
4. Zanubrutinib [inn]
5. Zanubrutinib [usan]
6. Ag9mhg098z
7. 1691249-45-2 (s-isomer)
8. (7s)-2-(4-phenoxyphenyl)-7-(1-(prop-2-enoyl)piperidin-4-yl)-4,5,6,7-tetrahydropyrazolo(1,5-a)pyrimidine-3-carboxamide
9. Bgb3111
10. (7s)-2-(4-phenoxyphenyl)-7-(1-prop-2-enoylpiperidin-4-yl)-4,5,6,7-tetrahydropyrazolo[1,5-a]pyrimidine-3-carboxamide
11. (7s)-4,5,6,7-tetrahydro-7-[1-(1-oxo-2-propen-1-yl)-4-piperidinyl]-2-(4-phenoxyphenyl)pyrazolo[1,5-a]pyrimidine-3-carboxamide
12. (s)-7-(1-acryloylpiperidin-4-yl)-2-(4-phenoxyphenyl)-4,5,6,7-tetrahydropyrazolo[1,5-a]pyrimidine-3-carboxamide
13. Pyrazolo(1,5-a)pyrimidine-3-carboxamide, 4,5,6,7-tetrahydro-7-(1-(1-oxo-2-propen-1-yl)-4-piperidinyl)-2-(4-phenoxyphenyl)-, (7s)-
14. Brukinsa (tn)
15. Zanubrutinib [mi]
16. Zanubrutinib (usan/inn)
17. Zanubrutinib [usan:inn]
18. Unii-ag9mhg098z
19. Bgb-3111(zanubrutinib)
20. Zanubrutinib (bgb-3111)
21. Zanubrutinib [who-dd]
22. Gtpl9861
23. Chembl3936761
24. Schembl17842597
25. Bdbm250082
26. Dtxsid701026208
27. Zanubrutinib [orange Book]
28. Compound 27b [us9447106]
29. Bcp29110
30. Ex-a3602
31. Nsc823807
32. S8791
33. Zinc584641430
34. At18252
35. Db15035
36. Hy-101474a
37. Nsc-823807
38. Us9447106, 27b (peak 2)
39. Bs-15529
40. Bz168474
41. Cs-0021869
42. D11422
43. Bgb-3111; Bgb 3111; Bgb3111
44. A934931
45. 1651179-04-2
46. 7-(1-acryloyl-4-piperidinyl)-2-(4-phenoxyphenyl)-4,5,6,7-tetrahydropyrazolo(1,5-a)pyrimidine-3-carboxamide
| Molecular Weight | 471.5 g/mol |
|---|---|
| Molecular Formula | C27H29N5O3 |
| XLogP3 | 3.5 |
| Hydrogen Bond Donor Count | 2 |
| Hydrogen Bond Acceptor Count | 5 |
| Rotatable Bond Count | 6 |
| Exact Mass | 471.22703980 g/mol |
| Monoisotopic Mass | 471.22703980 g/mol |
| Topological Polar Surface Area | 103 Ų |
| Heavy Atom Count | 35 |
| Formal Charge | 0 |
| Complexity | 756 |
| Isotope Atom Count | 0 |
| Defined Atom Stereocenter Count | 1 |
| Undefined Atom Stereocenter Count | 0 |
| Defined Bond Stereocenter Count | 0 |
| Undefined Bond Stereocenter Count | 0 |
| Covalently Bonded Unit Count | 1 |
Zanubrutinib is indicated for the treatment of adult patients with mantle cell lymphoma (MCL) who have received at least one prior therapy. It is used to treat Waldenstrms macroglobulinemia in adults. Zanubrutinib is also indicated for the treatment of relapsed or refractory marginal zone lymphoma (MZL) in adults who have received at least one anti-CD20-based regimen.
Brukinsa as monotherapy is indicated for the treatment of adult patients with Waldenstrms macroglobulinaemia (WM) who have received at least one prior therapy, or in first line treatment for patients unsuitable for chemo-immunotherapy.
Zanubrutinib is an immunomodulating agent that decreases the survival of malignant B cells. It inhibits BTK by binding to its active site. It works to inhibit the proliferation and survival of malignant B cells to reduce the tumour size in mantle cell lymphoma.
Antineoplastic Agents
Substances that inhibit or prevent the proliferation of NEOPLASMS. (See all compounds classified as Antineoplastic Agents.)
Hematologic Agents
Drugs that act on blood and blood-forming organs and those that affect the hemostatic system. (See all compounds classified as Hematologic Agents.)
Protein Kinase Inhibitors
Agents that inhibit PROTEIN KINASES. (See all compounds classified as Protein Kinase Inhibitors.)
L01
L - Antineoplastic and immunomodulating agents
L01 - Antineoplastic agents
L01E - Protein kinase inhibitors
L01EL - Bruton's tyrosine kinase (btk) inhibitors
L01EL03 - Zanubrutinib
Absorption
Following oral administration of zanubrutinib 160 mg twice daily and 320 mg once daily, the mean (%CV) zanubrutinib steady-state concentrations were 2,295 (37%) ngh/mL and 2,180 (41%) ngh/mL, respectively. The mean Cmax (%CV) was 314 (46%) ng/mL following 160 mg twice daily and 543 (51%) ng/mL following 320 mg once daily. The Cmax and AUC of zanubrutinib increase in a dose-proportional manner and there is minimal systemic accumulation after repeated dosing. The median Tmax is 2 hours.
Route of Elimination
Following oral administration of 320 mg radiolabelled zanubrutinib, approximately 87% of the dose was excreted in the feces and about 8% of the dose was recovered in the urine, where less than 1% of the recovered drug comprised of unchanged parent drug.
Volume of Distribution
The geometric mean (%CV) apparent steady-state Vd is 881 (95%) L. The blood-to plasma ratio is about 0.7 to 0.8.
Clearance
The mean (%CV) apparent oral clearance (CL/F) of zanubrutinib is 182 (37%) L/h.
Zanubrutinib is predominantly metabolized by CYP3A4. Its metabolites have not been characterized.
Following administration of a single oral dose of 160 mg or 320 mg of zanubrutinib, the mean half-life is approximately 2 to 4 hours.
Bruton's tyrosine kinase (BTK) is a non-receptor kinase and a signalling molecule for the B cell receptors expressed on the peripheral B cell surface. The BCR signalling pathway plays a crucial role in normal B-cell development but also the proliferation and survival of malignant B cells in many B cell malignancies, including mantle-cell lymphoma (MCL). Once activated by upstream Src-family kinases, BTK phosphorylates phospholipase-C (PLC), leading to Ca2+ mobilization and activation of NF-B and MAP kinase pathways. These downstream cascades promote the expression of genes involved in B cell proliferation and survival. The BCR signalling pathway also induces the anti-apoptotic protein Bcl-xL and regulates the integrin 41 (VLA-4)-mediated adhesion of B cells to vascular cell adhesion molecule-1 (VCAM-1) and fibronectin via BTK. Apart from the direct downstream signal transduction pathway of B cells, BTK is also involved in chemokine receptor, Toll-like receptor (TLR) and Fc receptor signalling pathways. Zanubrutinib inhibits BTK by forming a covalent bond with cysteine 481 residue in the adenosine triphosphate (ATP)binding pocket of BTK, which is the enzyme's active site. This binding specificity is commonly seen with other BTK inhibitors. Due to this binding profile, zanubrutinib may also bind with varying affinities to related and unrelated ATP-binding kinases that possess a cysteine residue at this position. By blocking the BCR signalling pathway, zanubrutinib inhibits the proliferation, trafficking, chemotaxis, and adhesion of malignant B cells, ultimately leading to reduced tumour size. Zanubrutinib was also shown to downregulate programmed death-ligand 1 (PD-1) expression and cytotoxic T lymphocyte-associated antigen-4 (CTLA-4) on CD4+ T cells.
GDUFA
DMF Review : Reviewed
Rev. Date : 2023-06-27
Pay. Date : 2023-05-10
DMF Number : 38350
Submission : 2023-05-12
Status : Active
Type : II
NDC Package Code : 17337-0321
Start Marketing Date : 2023-03-15
End Marketing Date : 2026-12-31
Dosage Form (Strength) : POWDER (1kg/kg)
Marketing Category : BULK INGREDIENT

GDUFA
DMF Review : Reviewed
Rev. Date : 2023-08-08
Pay. Date : 2023-05-30
DMF Number : 38215
Submission : 2023-03-31
Status : Active
Type : II
NDC Package Code : 54893-0510
Start Marketing Date : 2024-03-27
End Marketing Date : 2027-12-31
Dosage Form (Strength) : POWDER (1kg/kg)
Marketing Category : BULK INGREDIENT
Registrant Name : Kukjeon Pharmaceutical Co., Ltd.
Registration Date : 2026-02-19
Registration Number : Su173-70-ND
Manufacturer Name : MSN Laboratories Private Limited, Unit-III
Manufacturer Address : Sy. No. 111/E & 111/EE, Cheriyal Village, Kandi Mandal, Sangareddy District, Pincode 502285, Telangana State, India

GDUFA
DMF Review : Reviewed
Rev. Date : 2025-08-06
Pay. Date : 2025-03-24
DMF Number : 39665
Submission : 2024-03-27
Status : Active
Type : II
NDC Package Code : 54893-0502
Start Marketing Date : 2023-03-31
End Marketing Date : 2027-12-31
Dosage Form (Strength) : POWDER (1kg/kg)
Marketing Category : BULK INGREDIENT

NDC Package Code : 17337-0322
Start Marketing Date : 2023-03-15
End Marketing Date : 2026-12-31
Dosage Form (Strength) : POWDER (1kg/kg)
Marketing Category : BULK INGREDIENT

NDC Package Code : 57572-0729
Start Marketing Date : 2025-09-25
End Marketing Date : 2026-12-31
Dosage Form (Strength) : POWDER (1kg/kg)
Marketing Category : BULK INGREDIENT

NDC Package Code : 24538-311
Start Marketing Date : 2019-11-14
End Marketing Date : 2026-12-31
Dosage Form (Strength) : POWDER (1kg/kg)
Marketing Category : BULK INGREDIENT
Registrant Name : Biwon Medison Korea Co., Ltd.
Registration Date : 2022-09-16
Registration Number : Su969-1-ND
Manufacturer Name : Changzhou SynTheAll Pharmaceutical Co., Ltd.
Manufacturer Address : 589 North Yulong Road, Xinbei District Changzhou, Jiangsu, 213127, China

FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]
GDUFA
DMF Review : Complete
Rev. Date : 2025-08-06
Pay. Date : 2025-03-24
DMF Number : 39665
Submission : 2024-03-27
Status : Active
Type : II

GDUFA
DMF Review : Complete
Rev. Date : 2023-08-08
Pay. Date : 2023-05-30
DMF Number : 38215
Submission : 2023-03-31
Status : Active
Type : II

GDUFA
DMF Review : Complete
Rev. Date : 2023-06-27
Pay. Date : 2023-05-10
DMF Number : 38350
Submission : 2023-05-12
Status : Active
Type : II

FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Registrant Name : Kukjeon Pharmaceutical Co., Ltd.
Registration Date : 2026-02-19
Registration Number : Su173-70-ND
Manufacturer Name : MSN Laboratories Private Lim...
Manufacturer Address : Sy. No. 111/E & 111/EE, Cheriyal Village, Kandi Mandal, Sangareddy District, Pincode ...

Registrant Name : Biwon Medison Korea Co., Ltd.
Registration Date : 2022-09-16
Registration Number : Su969-1-ND
Manufacturer Name : Changzhou SynTheAll Pharmace...
Manufacturer Address : 589 North Yulong Road, Xinbei District Changzhou, Jiangsu, 213127, China

FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]
API/FDF Prices: Book a Demo to explore the features and consider upgrading later
API Imports and Exports
| Importing Country | Total Quantity (KGS) |
Average Price (USD/KGS) |
Number of Transactions |
|---|
Upgrade, download data, analyse, strategize, subscribe with us
Details:
Zanubrutinib is a small molecule drug, which is currently being evaluated in Phase II clinical studies for the treatment of polyneuropathies.
Lead Product(s): Zanubrutinib,Inapplicable
Therapeutic Area: Neurology Brand Name: Undisclosed
Study Phase: Phase IIProduct Type: Miscellaneous
Sponsor: ClinOpsHub Srl (CRO)
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable February 06, 2026

Lead Product(s) : Zanubrutinib,Inapplicable
Therapeutic Area : Neurology
Highest Development Status : Phase II
Partner/Sponsor/Collaborator : ClinOpsHub Srl (CRO)
Deal Size : Inapplicable
Deal Type : Inapplicable
Zanubritnib and Anti-MAG Neuropathy
Details : Zanubrutinib is a small molecule drug, which is currently being evaluated in Phase II clinical studies for the treatment of polyneuropathies.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
February 06, 2026

Details:
Zanubrutinib is a small molecule drug, which is currently being evaluated in Phase II clinical studies for the treatment of lymphoma, mantle-cell.
Lead Product(s): Zanubrutinib,Sonrotoclax,CAR-T Cell Therapy
Therapeutic Area: Oncology Brand Name: Undisclosed
Study Phase: Phase IIProduct Type: Miscellaneous
Sponsor: BeOne Medicines
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable January 14, 2026

Lead Product(s) : Zanubrutinib,Sonrotoclax,CAR-T Cell Therapy
Therapeutic Area : Oncology
Highest Development Status : Phase II
Partner/Sponsor/Collaborator : BeOne Medicines
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Zanubrutinib is a small molecule drug, which is currently being evaluated in Phase II clinical studies for the treatment of lymphoma, mantle-cell.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
January 14, 2026

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Details:
In a private placement deal, Emavusertib will be funded to advance its development targeting IRAK4 in Chronic Lymphocytic Leukemia.
Lead Product(s): Emavusertib,Zanubrutinib
Therapeutic Area: Oncology Brand Name: CA-4948
Study Phase: Phase IIProduct Type: Miscellaneous
Sponsor: Laidlaw & Company
Deal Size: $80.8 million Upfront Cash: Undisclosed
Deal Type: Private Placement January 09, 2026

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Emavusertib,Zanubrutinib
Therapeutic Area : Oncology
Highest Development Status : Phase II
Partner/Sponsor/Collaborator : Laidlaw & Company
Deal Size : $80.8 million
Deal Type : Private Placement
Curis Closes $80.8M Private Placement
Details : In a private placement deal, Emavusertib will be funded to advance its development targeting IRAK4 in Chronic Lymphocytic Leukemia.
Product Name : CA-4948
Product Type : Miscellaneous
Upfront Cash : Undisclosed
January 09, 2026

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Details:
Private Placement of Emavusertib to support the development of IRAK4 inhibitor for Chronic Lymphocytic Leukemia.
Lead Product(s): Emavusertib,Zanubrutinib
Therapeutic Area: Oncology Brand Name: CA-4948
Study Phase: Phase IIProduct Type: Miscellaneous
Sponsor: Laidlaw & Company
Deal Size: $80.8 million Upfront Cash: Undisclosed
Deal Type: Private Placement January 07, 2026

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Emavusertib,Zanubrutinib
Therapeutic Area : Oncology
Highest Development Status : Phase II
Partner/Sponsor/Collaborator : Laidlaw & Company
Deal Size : $80.8 million
Deal Type : Private Placement
Curis Sets Pricing for Private Placement Raising up to $80.8M
Details : Private Placement of Emavusertib to support the development of IRAK4 inhibitor for Chronic Lymphocytic Leukemia.
Product Name : CA-4948
Product Type : Miscellaneous
Upfront Cash : Undisclosed
January 07, 2026

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Details:
Sonrotoclax is a small molecule drug candidate, which is currently being evaluated in Phase III clinical studies for the treatment of Leukemia, Lymphocytic, Chronic, B-Cell.
Lead Product(s): Sonrotoclax,Zanubrutinib
Therapeutic Area: Oncology Brand Name: Undisclosed
Study Phase: Phase IIIProduct Type: Miscellaneous
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable December 11, 2025

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Sonrotoclax,Zanubrutinib
Therapeutic Area : Oncology
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Sonrotoclax is a small molecule drug candidate, which is currently being evaluated in Phase III clinical studies for the treatment of Leukemia, Lymphocytic, Chronic, B-Cell.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
December 11, 2025

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Details:
Emavusertib is a small molecule drug candidate, which is currently being evaluated in Phase II clinical studies for the treatment of Leukemia, Lymphocytic, Chronic, B-Cell.
Lead Product(s): Emavusertib,Zanubrutinib
Therapeutic Area: Oncology Brand Name: Undisclosed
Study Phase: Phase IIProduct Type: Miscellaneous
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable December 09, 2025

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Emavusertib,Zanubrutinib
Therapeutic Area : Oncology
Highest Development Status : Phase II
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Emavusertib is a small molecule drug candidate, which is currently being evaluated in Phase II clinical studies for the treatment of Leukemia, Lymphocytic, Chronic, B-Cell.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
December 09, 2025

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Details:
Zanubrutinib is a Small Molecule drug candidate drug candidate, which is currently being evaluated in Phase IV clinical studies for the treatment of Waldenstrom Macroglobulinemia.
Lead Product(s): Zanubrutinib,Inapplicable
Therapeutic Area: Oncology Brand Name: Undisclosed
Study Phase: Phase IVProduct Type: Miscellaneous
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable September 11, 2025

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Zanubrutinib,Inapplicable
Therapeutic Area : Oncology
Highest Development Status : Phase IV
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Zanubrutinib is a Small Molecule drug candidate drug candidate, which is currently being evaluated in Phase IV clinical studies for the treatment of Waldenstrom Macroglobulinemia.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
September 11, 2025

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Details:
BG-71332 (Sonrotoclax) is a Other Small Molecule drug candidate, which is currently being evaluated in Phase I clinical studies for the treatment of unspecified medical condition.
Lead Product(s): Sonrotoclax,Zanubrutinib
Therapeutic Area: Undisclosed Brand Name: BG-71332
Study Phase: Phase IProduct Type: Miscellaneous
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable August 26, 2025

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Sonrotoclax,Zanubrutinib
Therapeutic Area : Undisclosed
Highest Development Status : Phase I
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Zanubrutinib + Sonrotoclax FDC Tablet Bioavailability & Food Effect In Healthy Adults
Details : BG-71332 (Sonrotoclax) is a Other Small Molecule drug candidate, which is currently being evaluated in Phase I clinical studies for the treatment of unspecified medical condition.
Product Name : BG-71332
Product Type : Miscellaneous
Upfront Cash : Inapplicable
August 26, 2025

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Details:
Mosunetuzumab is a Antibody drug candidate, which is currently being evaluated in Phase I/ Phase II clinical studies for the treatment of Leukemia.
Lead Product(s): Mosunetuzumab,Ibrutinib,Acalabrutinib,Zanubrutinib,Pirtobrutinib
Therapeutic Area: Oncology Brand Name: Undisclosed
Study Phase: Phase I/ Phase IIProduct Type: Antibody, Unconjugated
Sponsor: Inhye Ahn
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable July 06, 2025

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Mosunetuzumab,Ibrutinib,Acalabrutinib,Zanubrutinib,Pirtobrutinib
Therapeutic Area : Oncology
Highest Development Status : Phase I/ Phase II
Partner/Sponsor/Collaborator : Inhye Ahn
Deal Size : Inapplicable
Deal Type : Inapplicable
Mosunetuzumab for CLL MRD Clearance
Details : Mosunetuzumab is a Antibody drug candidate, which is currently being evaluated in Phase I/ Phase II clinical studies for the treatment of Leukemia.
Product Name : Undisclosed
Product Type : Antibody, Unconjugated
Upfront Cash : Inapplicable
July 06, 2025

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Details:
Brukinsa (zanubrutinib) is an orally available, small molecule inhibitor of Bruton’s tyrosine kinase (BTK) approved for the treatment chronic lymphocytic leukemia.
Lead Product(s): Zanubrutinib,Inapplicable
Therapeutic Area: Oncology Brand Name: Brukinsa
Study Phase: Approved FDFProduct Type: Miscellaneous
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable June 11, 2025

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Zanubrutinib,Inapplicable
Therapeutic Area : Oncology
Highest Development Status : Approved FDF
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
U.S. FDA Approves Tablet Formulation of BeOne’s BRUKINSA® for All Approved Indications
Details : Brukinsa (zanubrutinib) is an orally available, small molecule inhibitor of Bruton’s tyrosine kinase (BTK) approved for the treatment chronic lymphocytic leukemia.
Product Name : Brukinsa
Product Type : Miscellaneous
Upfront Cash : Inapplicable
June 11, 2025

FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]TERT-BUTYL (E)-4-(3-(DIMETHYLAMINO)ACRYLOYL)PIPERI...
CAS Number : 1799799-87-3
End Use API : Zanubrutinib
About The Company : Founded with a mission to transform strategic capital into specialty chemicals, Ami Group focuses on Agrochemicals, Cosmetics, and Polymers. Ami Organics Ltd. i...

1-(TERT-BUTOXYCARBONYL) PIPERIDINE-4-CARBOXYLIC AC...
CAS Number : 84358-13-4
End Use API : Zanubrutinib
About The Company : Founded with a mission to transform strategic capital into specialty chemicals, Ami Group focuses on Agrochemicals, Cosmetics, and Polymers. Ami Organics Ltd. i...

3-Amino-4-cyano-5-(4-phenoxyphenyl)pyrazole
CAS Number : 330792-70-6
End Use API : Zanubrutinib
About The Company : Integrin Life Sciences Pvt. Ltd. is one of the growing pharmaceutical API, advanced chemical intermediates manufacturing companies in India. Our Plant is Locate...

tert-Butyl (E)-4-(3-(Dimethylamino)acryloyl)piperi...
CAS Number : 1799799-87-3
End Use API : Zanubrutinib
About The Company : Integrin Life Sciences Pvt. Ltd. is one of the growing pharmaceutical API, advanced chemical intermediates manufacturing companies in India. Our Plant is Locate...

3-Amino-4-Cyano-5-(4-Phenoxyphenyl)pyrazole
CAS Number : 330792-70-6
End Use API : Zanubrutinib
About The Company : Royal pharma was started in 2007 – it’s a small scale Advanced Intermediates Manufacturing company. Facilities are in accordance to GMP standards. Currently...

4-acetyl-piperidine-1-carboxylic acid tert-butyl e...
CAS Number : 206989-61-9
End Use API : Zanubrutinib
About The Company : Established in 2000, Shodhana Laboratories offers a wide range of APIs and intermediates and caters to the generic and custom requirements of some of the most p...

Tert-butyl (E)-4-(3-(dimethylamino)acryloyl)piperi...
CAS Number : 1799799-87-3
End Use API : Zanubrutinib
About The Company : VIDGAS is dedicated to delivering the highest quality SFC and HPLC purification and isolation solutions to clients across the pharmaceutical, biopharmaceutical,...

tert-butyl 4-(3-cyano-2-(4-phenoxyphenyl)pyrazolo[...
CAS Number : 2190506-55-7
End Use API : Zanubrutinib
About The Company : VIDGAS is dedicated to delivering the highest quality SFC and HPLC purification and isolation solutions to clients across the pharmaceutical, biopharmaceutical,...

FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Global Sales Information
Patents & EXCLUSIVITIES
ABOUT THIS PAGE
68
PharmaCompass offers a list of Zanubrutinib API manufacturers, exporters & distributors, which can be sorted by GMP, USDMF, JDMF, KDMF, CEP (COS), WC, Price,and more, enabling you to easily find the right Zanubrutinib manufacturer or Zanubrutinib supplier for your needs.
Send us enquiries for free, and we will assist you in establishing a direct connection with your preferred Zanubrutinib manufacturer or Zanubrutinib supplier.
PharmaCompass also assists you with knowing the Zanubrutinib API Price utilized in the formulation of products. Zanubrutinib API Price is not always fixed or binding as the Zanubrutinib Price is obtained through a variety of data sources. The Zanubrutinib Price can also vary due to multiple factors, including market conditions, regulatory modifications, or negotiated pricing deals.
A Zanubrutinib manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of Zanubrutinib, including repackagers and relabelers. The FDA regulates Zanubrutinib manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. Zanubrutinib API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.
A Zanubrutinib supplier is an individual or a company that provides Zanubrutinib active pharmaceutical ingredient (API) or Zanubrutinib finished formulations upon request. The Zanubrutinib suppliers may include Zanubrutinib API manufacturers, exporters, distributors and traders.
click here to find a list of Zanubrutinib suppliers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PharmaCompass.
A Zanubrutinib DMF (Drug Master File) is a document detailing the whole manufacturing process of Zanubrutinib active pharmaceutical ingredient (API) in detail. Different forms of Zanubrutinib DMFs exist exist since differing nations have different regulations, such as Zanubrutinib USDMF, ASMF (EDMF), JDMF, CDMF, etc.
A Zanubrutinib DMF submitted to regulatory agencies in the US is known as a USDMF. Zanubrutinib USDMF includes data on Zanubrutinib's chemical properties, information on the facilities and procedures used, and details about packaging and storage. The Zanubrutinib USDMF is kept confidential to protect the manufacturer’s intellectual property.
click here to find a list of Zanubrutinib suppliers with USDMF on PharmaCompass.
In Korea, the Ministry of Food and Drug Safety (MFDS) is in charge of regulating pharmaceutical products and services.
Pharmaceutical companies submit a Zanubrutinib Drug Master File in Korea (Zanubrutinib KDMF) to the MFDS, which includes comprehensive information about the production, processing, facilities, materials, packaging, and testing of Zanubrutinib. The MFDS reviews the Zanubrutinib KDMF as part of the drug registration process and uses the information provided in the Zanubrutinib KDMF to evaluate the safety and efficacy of the drug.
After submitting a Zanubrutinib KDMF to the MFDS, the registered manufacturer can provide importers or distributors with the registration number without revealing confidential information to Korean business partners. Applicants seeking to register their Zanubrutinib API can apply through the Korea Drug Master File (KDMF).
click here to find a list of Zanubrutinib suppliers with KDMF on PharmaCompass.
National Drug Code is a comprehensive database maintained by the FDA that contains information on all drugs marketed in the US. This directory includes information about finished drug products, unfinished drug products, and compounded drug products, including those containing Zanubrutinib as an active pharmaceutical ingredient (API).
The FDA updates the NDC directory daily. The NDC numbers for Zanubrutinib API and other APIs are published in this directory by the FDA.
The NDC unfinished drugs database includes product listing information submitted for all unfinished drugs, such as active pharmaceutical ingredients (APIs), drugs intended for further processing and bulk drug substances for compounding.
Pharmaceutical companies that manufacture Zanubrutinib as an active pharmaceutical ingredient (API) must furnish the FDA with an updated record of all drugs that they produce, prepare, propagate, compound, or process for commercial distribution in the US at their facilities.
The NDC directory also contains data on finished compounded human drug products that contain Zanubrutinib and are produced by outsourcing facilities. While these outsourcing facilities are not mandated to assign a Zanubrutinib NDC to their finished compounded human drug products, they may choose to do so.
click here to find a list of Zanubrutinib suppliers with NDC on PharmaCompass.
Zanubrutinib Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.
GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).
PharmaCompass offers a list of Zanubrutinib GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right Zanubrutinib GMP manufacturer or Zanubrutinib GMP API supplier for your needs.
A Zanubrutinib CoA (Certificate of Analysis) is a formal document that attests to Zanubrutinib's compliance with Zanubrutinib specifications and serves as a tool for batch-level quality control.
Zanubrutinib CoA mostly includes findings from lab analyses of a specific batch. For each Zanubrutinib CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.
Zanubrutinib may be tested according to a variety of international standards, such as European Pharmacopoeia (Zanubrutinib EP), Zanubrutinib JP (Japanese Pharmacopeia) and the US Pharmacopoeia (Zanubrutinib USP).